Blade therapeutics autotaxin
WebMay 18, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential ... WebSep 4, 2024 · Cudetaxestat (BLD-0409), which is Blade's lead investigational medicine, is a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is ...
Blade therapeutics autotaxin
Did you know?
WebBlade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. ... Blade's second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2024. WebLandos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. …
WebSep 4, 2024 · SAN FRANCISCO, September 04, 2024--Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases ... WebJun 13, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for the ...
WebWe are positioned to build a pipeline across a range of fibrotic and neurodegenerative diseases. Learn More. Cudetaxestat. (Fibrosis) Phase 2. BLD-2184. … Blade Therapeutics is advancing a differentiated pipeline of oral, small … Blade Therapeutics is located at 442 Littlefield Avenue South San Francisco, … Press Releases and Articles for Blade Therapeutics. Blade is advancing … Blade Therapeutics is a biopharmaceutical company focused on developing cutting … Autotaxin/LPA and calpains each play distinct roles within the biological … Targeting Calpains in Fibrosis. Dimeric calpains (CAPNs 1, 2, 9) are calcium … Diseases characterized by uncontrolled, progressive fibrosis include idiopathic … references. Weber, 2014, Biomed Res Intl. 2014: 701758. Menzies, 2015, Cell … WebProvides specialty pharmaceutical and biopharmaceutical products, related services and targeted therapy management programs. Includes plans, resources and company …
WebAug 1, 2024 · San Francisco, CA-based Blade Therapeutics believes its autotaxin inhibitor cudetaxestat can avoid the toxicity issues that befell Galapagos’s ziritaxestat in 2024.
WebNov 8, 2024 · Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a noncompetitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential ... katy taylor footballWebApr 4, 2024 · Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases. lay shower tileWebAccord Healthcare, Inc., the US subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company headquartered in Durham, North Carolina. Through its … katy tennis academy reviewsWebOct 14, 2024 · Blade Therapeutics, Inc. today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc). Cudetaxestat is an investigational non-competitive autotaxin inhibitor in clinical development for IPF. lays hot wingshttp://www.accredo.com/ lay show cattleWebAug 25, 2024 · Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that … laysick eye costWebNov 8, 2024 · The combined company is expected to have a post-transaction enterprise value of approximately $352.8 million when it is finalized. Blade Therapeutics will … laysick medicine